摘要来源: j int aids soc。 2020年10月; 23(10):E25628。 PMID: 33073530“> 33073530
katti r crakes
摘要:
简介:>
METHODS: We formulated a potent HIV inhibitor Griffithsin (Grft) in a mucoadhesive silk fibroin (SF) drug delivery platform and tested the application在体内的非人类灵长类动物模型以及临床前的人类宫颈和结直肠组织外植体模型中。阴道和直肠室均在恒河猕猴中评估(粘液接收SF(n = 4),无SF(n = 7)和SF-GRFT(n = 11)的Mulatta)。 In this study, we evaluated the composition of local microbiota, inflammatory cytokine production, histopathological changes in the vaginal and rectal compartments and mucosal protection after ex vivo SHIV challenge.
RESULTS: Effective Grft release and retention in mucosal tissues from the SF-Grft platform resulted in protection against人类宫颈和结直肠组织中的HIV,以及猕猴阴道和直肠组织中的SHIV挑战。 Mucoadhesion of SF-Grft inserts did not cause any inflammatory responses or changes in local microbiota.
CONCLUSIONS: We demonstrated that in vivo delivery of SF-Grft in rhesus macaques fully protects against SHIV challenge ex vivo after two hours of application and is safe to use in both the vaginal和直肠隔室。我们的研究证明IDES支持丝绸纤维蛋白的发展是一种非常有前途的,用户友好的艾滋病毒预防模态,以解决HIV感染中的全球差异。